Format

Send to

Choose Destination
Hum Vaccin Immunother. 2013 May;9(5):1073-7. doi: 10.4161/hv.23587. Epub 2013 Jan 28.

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Author information

1
INSERM; Unité Mixte de Recherche 1098; Besançon, France; Etablissement Français du Sang de Bourgogne Franche-Comté; UMR1098; Besançon cedex, France; Université de Franche-Comté; UMR1098 ; SFR IBCT; Besançon, France; CHRU de Besançon ; Service d'Oncologie; Besançon, France.

Abstract

Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents a powerful approach to the fully use of CD4(+) T cell-based immunotherapy.

KEYWORDS:

CD4 T cell; cancer vaccine; helper peptide; telomerase

PMID:
23357860
PMCID:
PMC3899142
DOI:
10.4161/hv.23587
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center